[Experiences with a new spasmolytic from the group of 1,3-dioxolan-4-on derivatives].
D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D001660:Biliary Tract Diseases / Q000188:drug therapy; D004149:Dioxoles / Q000627:therapeutic use* / Q000633:toxicity; D004361:Drug Tolerance; D004378:Duodenal Diseases / Q000188:drug therapy; D004412:Dysmenorrhea / Q000188:drug therapy; D004941:Esophagitis / Q000188:drug therapy; D005260:Female; D005756:Gastritis / Q000188:drug therapy; D006331:Heart Diseases / Q000188:drug therapy; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy; D009132:Muscles / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D013035:Spasm / Q000188:drug therapy*
D004149:Dioxoles; D010880:Piperidines
Erfahrungen mit einem neuartigen Spasmolyticum aus der Gruppe der 1,3-Dioxolan-4-on-Derivate.